Estrella Immunopharma and TradeUP Acquisition today announced the closing of their business combination.
Estrella is a preclinical-stage biopharmaceutical company developing T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
Estrella stock and warrants will begin trading Oct. 2 on the Nasdaq under the symbols ESLA and ESLAW.
TradeUP shareholders approved the deal in July, although the SPAC’s $45.4 million cash in trust at deal announcement last October had withered to about $1 million going into the merger vote.
Following shareholder approval of the merger, the SPAC secured a $10 million PIPE to go with other financing, which ultimately got the deal across the finish line. Read more.
